• The association between lithium use and neurocognitive performance in patients with bipolar disorder 

      Burdick, Katherine E.; Millett, Caitlin E.; Russo, Manuela; Alda, Martin; Alliey-Rodriguez, Ney; Anand, Amit; Balaraman, Yokesh; Berrettini, Wade H.; Bertram, Holli; Calabrese, Joseph R.; Calkin, Cynthia V.; Conroy, Carla; Coryell, William; DeModena, Anna; Feeder, Scott; Fisher, Carrie; Frazier, Nicole; Frye, Mark; Gao, Keming; Garnham, Julie; Gershon, Elliot S.; Glazer, Kara; Goes, Fernando S.; Goto, Toyomi; Harrington, Gloria J.; Jakobsen, Petter; Kamali, Masoud; Kelly, Marisa; Leckband, Susan G.; Løberg, Else-Marie; Lohoff, Falk W.; Maihofer, Adam X.; McCarthy, Michael J.; McInnis, Melvin; Morken, Gunnar; Nievergelt, Caroline M.; Nurnberger, John I.; Oedegaard, Ketil J.; Ortiz, Abigail; Ritchey, Megan; Ryan, Kelly; Schinagle, Martha; Schwebel, Candice; Shaw, Martha; Shilling, Paul D.; Slaney, Claire; Stapp, Emma; Tarwater, Bruce; Zandi, Peter P.; Kelsoe, John R. (Journal article; Peer reviewed, 2020)
      Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by ...